Marie E McNeely1, Gammon M Earhart. 1. Program in Physical Therapy, Washington University in St Louis, St Louis, MO 63108, USA.
Abstract
BACKGROUND: Dopaminergic medications and subthalamic nucleus deep brain stimulation (STN-DBS) alleviate motor symptoms in Parkinson disease, but balance and gait are more variably affected. Balance reports are particularly inconsistent. Further, despite their prevalence in daily life, complex gait situations including backward and dual task gait are rarely studied. We aimed to assess how medications, STN-DBS, and both therapies combined affect balance and complex gait. METHODS: Twelve people with Parkinson disease were evaluated OFF medication with STN-DBS OFF and ON as well as ON medication with STN-DBS OFF and ON. Motor impairment was measured with the Movement Disorder Society Unified Parkinson Disease Rating Scale motor section (MDS-UPDRS-III). The Mini-Balance Evaluations Systems Test, timed-up-and-go, and dual task timed-up-and-go measured balance and mobility. Preferred-pace forward, fast as possible forward, backward, dual task forward, and dual task backward gait were also analyzed. RESULTS: Medication improved MDS-UPDRS-III scores, dual task timed-up-and-go, and stride length across all gait tasks. STN-DBS improved MDS-UPDRS-III scores, balance scores, dual task timed-up-and-go, and stride length and velocity across all gait tasks. Medication and STN-DBS combined did not provide additional benefits over either therapy alone. CONCLUSIONS: Overall, dopaminergic medications and STN-DBS provided similar improvements in balance and gait tasks, although the effects of STN-DBS were stronger, potentially due to reductions in medication doses after surgery. Lack of synergistic effect of treatments may suggest both therapies improve balance and gait by influencing similar neural pathways.
BACKGROUND: Dopaminergic medications and subthalamic nucleus deep brain stimulation (STN-DBS) alleviate motor symptoms in Parkinson disease, but balance and gait are more variably affected. Balance reports are particularly inconsistent. Further, despite their prevalence in daily life, complex gait situations including backward and dual task gait are rarely studied. We aimed to assess how medications, STN-DBS, and both therapies combined affect balance and complex gait. METHODS: Twelve people with Parkinson disease were evaluated OFF medication with STN-DBS OFF and ON as well as ON medication with STN-DBS OFF and ON. Motor impairment was measured with the Movement Disorder Society Unified Parkinson Disease Rating Scale motor section (MDS-UPDRS-III). The Mini-Balance Evaluations Systems Test, timed-up-and-go, and dual task timed-up-and-go measured balance and mobility. Preferred-pace forward, fast as possible forward, backward, dual task forward, and dual task backward gait were also analyzed. RESULTS: Medication improved MDS-UPDRS-III scores, dual task timed-up-and-go, and stride length across all gait tasks. STN-DBS improved MDS-UPDRS-III scores, balance scores, dual task timed-up-and-go, and stride length and velocity across all gait tasks. Medication and STN-DBS combined did not provide additional benefits over either therapy alone. CONCLUSIONS: Overall, dopaminergic medications and STN-DBS provided similar improvements in balance and gait tasks, although the effects of STN-DBS were stronger, potentially due to reductions in medication doses after surgery. Lack of synergistic effect of treatments may suggest both therapies improve balance and gait by influencing similar neural pathways.
Authors: M Ferrarin; M Rizzone; B Bergamasco; M Lanotte; M Recalcati; A Pedotti; L Lopiano Journal: Exp Brain Res Date: 2004-10-22 Impact factor: 1.972
Authors: S Colnat-Coulbois; G C Gauchard; L Maillard; G Barroche; H Vespignani; J Auque; Ph P Perrin Journal: J Neurol Neurosurg Psychiatry Date: 2005-06 Impact factor: 10.154
Authors: H Russmann; J Ghika; J-G Villemure; B Robert; J Bogousslavsky; P R Burkhard; F J G Vingerhoets Journal: Neurology Date: 2004-11-23 Impact factor: 9.910
Authors: R Norel; C Agurto; S Heisig; J J Rice; H Zhang; R Ostrand; P W Wacnik; B K Ho; V L Ramos; G A Cecchi Journal: NPJ Parkinsons Dis Date: 2020-06-12
Authors: Alfonso Fasano; Camila C Aquino; Joachim K Krauss; Christopher R Honey; Bastiaan R Bloem Journal: Nat Rev Neurol Date: 2015-01-13 Impact factor: 42.937
Authors: Miriam R Rafferty; Janey Prodoehl; Julie A Robichaud; Fabian J David; Cynthia Poon; Lisa C Goelz; David E Vaillancourt; Wendy M Kohrt; Cynthia L Comella; Daniel M Corcos Journal: J Neurol Phys Ther Date: 2017-01 Impact factor: 3.649
Authors: Carsten Buhmann; Torge Huckhagel; Katja Engel; Alessandro Gulberti; Ute Hidding; Monika Poetter-Nerger; Ines Goerendt; Peter Ludewig; Hanna Braass; Chi-Un Choe; Kara Krajewski; Christian Oehlwein; Katrin Mittmann; Andreas K Engel; Christian Gerloff; Manfred Westphal; Johannes A Köppen; Christian K E Moll; Wolfgang Hamel Journal: PLoS One Date: 2017-07-05 Impact factor: 3.240